SCHEMBL8255489

SCHEMBL8255489

N#Cc1ccc2c(c1)S(=O)(=O)CC2N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 3/20 0.42
CHRNA1 P02708 1/20 0.37
CHRNG P07510 1/20 0.37
CHRNB1 P11230 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRND Q07001 1/20 0.37
SLC6A4 P31645 1/20 0.35
KDM1A O60341 3/20 0.35
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
PDGFRB P09619 1/20 0.33
FGFR1 P11362 1/20 0.33
FLT1 P17948 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17050360 0.84 CA2 (0.38) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL24075854 0.81 CHRNA1 (0.37) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL19695677 0.81 CHRNA1 (0.37) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL15491211 0.81 CHRNA1 (0.37) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL24090485 0.78 CHRNA1 (0.36) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL10210657 0.77 CHRNA1 (0.38) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL24090486 0.75 SLC6A4 (0.34) CHRNA1CHRNGCHRNB1CHRNB2CHRNB4
SCHEMBL7424900 0.74 PPARA (0.45) KMT2A
SCHEMBL10444095 0.73 CA1 (0.36) VEGFACHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL20992182 0.72 CHRNA1 (0.36) CHRNA1CHRNGCHRNB1CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
WO-2006128184-A2 PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS ALANTOS-PHARMACEUTICALS, INC. (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 VEGFA 2608/4885CHRNA1 4860/4885CHRNG 4708/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 VEGFA 2608/4885CHRNA1 4860/4885CHRNG 4708/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 VEGFA 2608/4885CHRNA1 4860/4885CHRNG 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.